Objectives-To determine the prevalence of vertebral fracture in postmenopausal women with steroid treated rheumatoid arthritis (RA), and whether the risk of vertebral fracture could be predicted from measurements of bone mineral density (BMD).
Bone loss is a well recognised complication of rheumatoid arthritis (RA) and is not only localised around inflamed joints, but also affects skeletal sites distant from them, such as the lumbar spine and proximal femur.'`5
The aetiology of bone loss is likely to be multifactorial. Studies have demonstrated that disease activity is a determinant of bone loss in RA6 and may be mediated by the release of bone resorbing cytokines such as interleukin-1 (IL-1) and tumour necrosis factor (TNF) from the inflamed synovium.7 Other determinants of bone loss in RA may include physical inactivity,6 8 9 weight loss, 1 and the use of drugs such as corticosteroids." 12 In type I osteoporosis, the risk of vertebral fracture has been shown to increase two-to threefold for every SD decrease in bone mineral density of the lumbar spine (LS-BMD) below the expected value. 3 The risk ofvertebral fracture may therefore be expected to be increased in RA. Because vertebral fractures may be asymptomatic, their prevalence can only be determined from radiological surveys. Spector et al recently reported that the rate of vertebral fracture was increased in postmenopausal women with RA, some of whom were treated with oral corticosteroids, but that BMD of the lumbar spine and femoral neck was not lower in the women with vertebral fracture.'4 They did not compare BMD of the women with RA and the controls. Their results suggest that the relationship between vertebral fracture risk and BMD may differ in secondary osteoporosis compared with type I osteoporosis.
The aims of this study were to determine the prevalence of vertebral fracture in postmenopausal women with RA who had been treated with corticosteroids, in comparison with population based controls, and to determine whether BMD measurement could predict the risk of vertebral fracture in these women. 24 hour urine calcium excretion all within normal limits).
Subjects and methods

DEFINITION OF VERTEBRAL FRACTURE
Each subject had anteroposterior (AP) and lateral radiographs of the thoracic and lumbar spine, taken at a standard target to film distance of 100 cm. Thoracic films were centred on vertebra T7 and lumbar films on vertebra L2. Vertebral deformities were defined according to the morphometric criteria of Eastell et al. 17 In this method the anterior (ha), posterior (hp) and mid (hm) height of each vertebra from T4 to L5 are measured on the lateral radiographs and deformities defined for each vertebra as:
O/o wedge = (hp -ha)/hp x 100 % biconcavity = (hp -hm)/hp X 100 % compression = (hp' -hp)/hp' X 100 where hp' is the posterior height of the vertebra below or the vertebra above. The deformities for each vertebra were compared with published normative data from women'7 and a vertebra was considered to be fractured if it had a deformity more than 3 SD less than the mean for that vertebra.
Marking of the radiographs was performed by a single observer. The AP radiographs were used to identify the vertebra and to take account of anomalous segmentation which we have shown to affect 16.5% of individuals. '8 Radiographs were assessed for the presence of vertebral deformities resulting from fracture or other causes, by a consultant radiologist (NAB, DJM) blind to the results from the morphometric analysis of the radiographs.
BONE DENSITOMETRY BMD of the lumbar spine, femoral neck (FN-BMD), and total body (TB-BMD) were measured by dual energy x ray absorptiometry (Hologic QDR 1000/W, Hologic Inc, Waltham, MA) in all the women with RA and the 20 healthy women from the population based group (aged 54-77 (mean 63) years). The reproducibility of BMD measurements using the Hologic QDR 1000/W was assessed from duplicate measurements in 20 women aged years, of whom 12 had RA. The precision error, calculated as a coefficient of variation, was 1-4% at the lumbar spine, and 2-9% at the femoral neck. Vertebrae which were identified as being fractured within the region of analysis (Li to L4) were excluded from the analysis to avoid artificial overestimation of measured LS-BMD.
The BMD of the 20 healthy controls, measured previously using a different densitometer (Lunar DPX, Lunar Corp, Madison WI) was representative of the 375 women in the population based group from which they were selected (mean Z scores normalised for age and weight: -0 01, 95% confidence interval (NS: 95% CI of difference, -9 to 1%).
Vertebral deformities both in women with RA and in controls were evenly distributed between the thoracic and lumbar spine. In the women with RA, 63% of deformities were of thoracic vertebrae, and in the controls, 61% of deformities were of thoracic vertebrae. This reflects the proportion of vertebrae assessed (T4 to L5, of which 64% were thoracic). Table 2 shows the number of subjects with single and multiple vertebral deformities. In the women with RA the number of these deformities did not relate to factors such as BMD, age, height, weight, disease duration, or steroid treatment (mean daily or cumulative dose, or duration of treatment).
BONE MINERAL DENSITY Table 3 shows the decrease in BMD in the women with RA compared with the healthy controls, and the figure illustrates the decrease in BMD expressed as Z scores. The BMD in RA was decreased by 10-16%, or 0-8-1-5 SD units: the mean (95% CI) Z scores were -0.79 (-1-05 to -0 51) (lumbar spine), -1-15 (-1-36 to -0 94) (neck of femur), and -1-46 (-1.81 to -111) (total body). There was no difference in BMD at any site between those women with and without vertebral deformities (table 3) , and the women with deformities did not differ from those lacking them with respect to age, height, weight, disease duration, or steroid treatment (mean daily or cumulative dose, or duration of treatment).
In the women with RA, LS-BMD correlated with body weight (r = 0 39, p < 0 001), which was lower than that of healthy controls (58-7 v 64-6 kg; 95% CI of difference -10-7 to -1 1 kg). In a multiple linear regression model, 
Discussion
This study suggests that postmenopausal women with steroid treated RA are at increased risk of vertebral fracture, but the proportions of risk attributable to the disease itself or to the concomitant steroid treatment cannot be determined from our data. The greatest risk of vertebral fracture appeared to be in the younger women with RA, but the number of patients younger than 60 years was small, as is reflected by the wide confidence limits for the odds ratio. The distribution of vertebral deformities between the thoracic and lumbar vertebrae did not differ between the groups, and the numbers of subjects with multiple vertebral deformities were similar (table 2) .
The increased risk of fracture is in agreement with the one previous study in which morphometric criteria were used to define vertebral fractures in RA. 4 The lower odds ratio for vertebral fracture in that study may reflect the fact that only 34% of the women in the study were receiving corticosteroids, though we have found no association between BMD and duration of steroid use, mean daily dose, or cumulative dose, and no difference in steroid use between the women with and without vertebral fractures.
The high odds ratio for vertebral fracture could also result from an underestimate of the prevalence of vertebral deformities in the control population. However, the marking of the radiographs of both the patients and controls was performed by a single individual, and the prevalence of vertebral deformities identified by the morphometric algorithm was in very close agreement with the prevalence rates defined by experienced radiologists (NAB and DJM), who were blind to the results of the morphometric analysis. The prevalence of vertebral deformities within the population based group was also very similar to that established in another UK population using the same morphometric algorithm. 20 In type I osteoporosis, we would expect an odds ratio for vertebral fracture risk greater than 6 to be associated with a decrease in LS-BMD of 2-3 SD, yet in this cohort of women with steroid treated RA, the LS-BMD was decreased by only 0 79 SD. As the SD of LS-BMD measurements was significantly smaller in our control group compared with the population from which they were selected, there may be an overestimate of the Z score. The smaller decrease in LS-BMD than expected for the prevalence of vertebral fracture, and the fact that there was no difference in LS-BMD between the women with and without vertebral fractures, could be artefactual or could reflect defective bone quality in the women with steroid treated RA. Alternatively, it may reflect the impact on the skeleton of other factors associated with RA, such as the increased tendency of patients with arthritis to fall,2' or altered biomechanics of the spine resulting from these patients' multiple deformities.
Our results could have been explained if a high proportion of the vertebral deformities defined by the morphometric algorithm in the women with RA were the result of pathology other than vertebral fracture. However, review of the spine radiographs by consultant radiologists did not support this idea. Similarly, there may have been a high proportion of traumatic vertebral fractures, which would not necessarily be associated with low BMD. Although this is not easy to quantify, there was no supporting evidence from the case records. Another possibility was that the women with vertebral fractures had more severe degenerative disease of the spine which led to an artefactual increase in LS-BMD. This concept was not supported by review of the spine radiographs, and after exclusion of subjects with significant degenerative change of the lumbar spine from the analysis, (table 3) suggests that the poor diagnostic sensitivity of BMD measurement in steroid treated RA is the result of heterogeneity in bone quality rather than artefactual problems ofLS-BMD measurement in these women. BMD measurements are believed to reflect approximately 75% of the variability in bone strength;24 bone quality contributes to the remaining 25%: for example, there may be differences in the frequency of trabecular perforation, or in the elasticity of bone. The use of novel techniques of bone measurement such as ultrasound densitometry, which may reflect trabecular architecture, or lateral LS-BMD measurement by dual energy x ray absorptiometry (which may be a more sensitive measure of trabecular bone loss in corticosteroid induced osteoporosis than the anteroposterior technique we used25), may help to resolve this question.
The design of our study did not permit determination of the independent effects of steroid treatment and RA on the skeleton. There remains no consensus on the effect of low dose corticosteroid treatment on bone mass in RA. Although many studies have shown decreased BMD in patients treated with steroids compared with non-steroid-treated patients,3 5 11 others have failed to demonstrate this. 4 26 There is evidence that the deleterious effect of steroids may be restricted to the use of more than 5 mg of prednisolone daily in postmenopausal women with RA, and that doses of up to 7-5 mg daily may not be harmful to bone in premenopausal women and in men with RA.4 12 However, a greater adverse effect of corticosteroids in premenopausal women has been shown,27 while a decreased rate of loss of total body BMC has been demonstrated in patients receiving corticosteroids, despite their having a lower initial normalised bone mass than the non-steroid-treated patients.28 This suggested that the deleterious effect of steroid treatment may occur in the initial phase of treatment.
The possibility also exists that other medication may have influenced the development of osteoporosis and vertebral fractures in the women we studied. Although a multiple linear regression model failed to show either DMARD or NSAID treatment to influence BMD or vertebral fracture prevalence in this cohort, this does not exclude the possibility that these medications may have influenced the skeletal status of these women. Current medication may not be representative of previous medication, particularly in view of the long disease duration in these subjects. Similarly, it is not possible from a cross sectional study to determine the influence of these medications on underlying disease activity.
In summary, we have demonstrated a considerable increase in the risk of vertebral fracture in postmenopausal women with steroid treated RA. The relative effects of corticosteroid treatment and the disease itself could not be determined from this study. Although LS-BMD was significantly decreased in these women, the magnitude of this decrease could not fully explain the increase in risk of vertebral fracture. BMD measurements did not differentiate between women with and without vertebral fractures. We speculate that there may be a bone quality defect in steroid treated RA, perhaps mediated by increased bone turnover and increased trabecular perforation. We conclude that measurement of LS-BMD may not be a useful assessment of fracture risk in this form of secondary osteoporosis.
